Q1 earnings presentation materials for the fiscal year ending November 2026. Core DTx business centered on Medcle, primarily targeting insomnia disorders. Revenue driven by milestone recognition, operating loss widened. Key initiatives focus on expanding the pipeline and platform adoption such as SDS (clinical trial system) and QDTx.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4263","jir_company_name":"SUSMED,Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4263-20261106-01.pdf","jir_short_summary":"Q1 earnings presentation materials for the fiscal year ending November 2026. Core DTx business centered on Medcle, primarily targeting insomnia disorders. Revenue driven by milestone recognition, operating loss widened. Key initiatives focus on expanding the pipeline and platform adoption such as SDS (clinical trial system) and QDTx.","jir_summary":"### Overview of Results\nSUSMED,Inc. is expanding its business centered on a DTx development platform and the clinical trial support SUSMED SourceDataSync. Sales of Medcle began in June 2026; for the cumulative Q1 this fiscal year, business revenue was 227 million yen and operating loss was 61 million yen. The number of adopting medical institutions is assumed to expand from 194 facilities to around 1,000 facilities, and monthly prescriptions are expected to grow from 27 times\/month to 2,000 times\/month. The pipeline consists of 11 projects, and R&D expenses moved accordingly.\n\n### Future Policies and Key Initiatives\nPriority initiatives include strengthening promotion of the insomnia treatment app. Efforts will focus on establishing a direct sales structure, increasing awareness through event participation, conference presentations, and online seminars, and promoting disease awareness activities. The company will also continue to build operational track record of the clinical trial system, expand app adoption, and strengthen academic collaboration.","jir_financial_highlights":"Business Revenue: 227 million yen (Year-over-Year Unknown)\nOperating Loss: -61 million yen (Year-over-Year Unknown)\nFull-year Revenue Budget: 838 million yen (Progress Rate 27.2%)\nNumber of Medical Institutions Adopting Medcle: 1,000 facilities (Year-over-Year Unknown)\nMonthly Prescriptions: 2,000 times\/month (Year-over-Year Unknown)","jir_category":"","jir_hashtags":"#SUSMED, #DigitalHealth, #ClinicalTrialSolutions","jir_key_figures":"Business Revenue: 227 million yen\nOperating Loss: -61 million yen\nFull-year Budget: 838 million yen\nNumber of Medical Institutions Adopting Medcle: 1,000 facilities\nMonthly Prescriptions: 2,000 times\/month","jir_meta_title":"SUSMED,Inc. \u2014 Promotion of Insomnia Treatment App and Expansion of Clinical Trial Platform | Q1 Earnings Materials for FY ending Nov 2027","jir_meta_description":"Summary of SUSMED's business centered on DTx Medcle, operational track record of the SDS clinical trial support, key promotional initiatives, near-term outlook, and pipeline status.","jir_og_title":"SUSMED's Insomnia Treatment App and Expansion of Clinical Trial Platform","jir_og_description":"Disclosure of Medcle domestic sales launch and expansion strategy in the insomnia field, increased utilization of the SDS clinical trial system, and future pipeline and financial trends.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-11\\\",\\\"2027-02\\\",\\\"2027-05\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[227,?,?],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-11\\\",\\\"2027-02\\\",\\\"2027-05\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-?,-61,-?],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"DTx Product\\\",\\\"DTx Platform\\\"],\\\"datasets\\\":[{\\\"data\\\":[200,26],\\\"backgroundColor\\\":[\\\"#4f81bd\\\",\\\"#9bbb59\\\"]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-11\\\",\\\"2027-06\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Margin\\\",\\\"data\\\":[0.23,0.15],\\\"borderColor\\\":\\\"#e37b1f\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Guidance vs Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026 Q1\\\",\\\"2026 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Guidance\\\",\\\"data\\\":[0.25,0.28],\\\"backgroundColor\\\":\\\"#92d050\\\"},{\\\"label\\\":\\\"Actual\\\",\\\"data\\\":[0.23,0.22],\\\"backgroundColor\\\":\\\"#1f77b4\\\"}]}}\"}]","ir_related_company":58337,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-144024","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n